4//SEC Filing
Doyle Anthony 4
Accession 0001127602-24-029965
CIK 0000882796other
Filed
Dec 22, 7:00 PM ET
Accepted
Dec 23, 4:11 PM ET
Size
8.7 KB
Accession
0001127602-24-029965
Insider Transaction Report
Form 4
Doyle Anthony
Chief Financial Officer
Transactions
- Award
Common Stock
2024-12-19+120,700→ 380,328 total - Tax Payment
Common Stock
2024-12-19$7.39/sh−2,461$18,187→ 377,867 total - Award
Emp. Stock Option (Right to Buy)
2024-12-19+250,100→ 250,100 totalExercise: $7.39From: 2025-12-19Exp: 2034-12-19→ Common Stock (250,100 underlying)
Footnotes (3)
- [F1]Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.
- [F2]Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the Reporting Person.
- [F3]Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.
Documents
Issuer
BIOCRYST PHARMACEUTICALS INC
CIK 0000882796
Entity typeother
Related Parties
1- filerCIK 0001808688
Filing Metadata
- Form type
- 4
- Filed
- Dec 22, 7:00 PM ET
- Accepted
- Dec 23, 4:11 PM ET
- Size
- 8.7 KB